Published Date: 14 Mar 2023
Takotsubo syndrome is more common in women. Less is known about its occurrence in men. This study provides a description of the disease characteristics and incidence of TTTS in men.
Read Full NewsuniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]
Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.
Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.
ACR Convergence 2025 Recap: Late-Breaking Trials to Know
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial
1.
Interleukin-6 may boost prediction of obesity-related cancers
2.
After all, Pulled Myeloma Drug May Help Treat the Illness.
3.
No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer
4.
Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care
5.
Unlocking the secrets of the fibrotic fortress that surrounds and protects pancreatic cancer
1.
What are Acanthocytes? Understanding the Role of Spiky Red Blood Cells
2.
Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends
3.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
4.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
5.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation